Perspectives from CPhI Worldwide - Jan-Olav Henck - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Jan-Olav Henck

Jan-Olav Henck, PhD,
chief scientific officer
Aptuit


Add this Podcast feed to your media player



Jan-Olav Henck, PhD, chief scientific officer at Aptuit, discusses strategies and considerations in polymorph screening with Patricia Van Arnum, senior editor of Pharmaceutical Technology (Posted November 2011).

 
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
11/8/2011
 Click here